Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with FLOT in Gastric/GEJ Cancer (DANTE)
NCT03421288Phase 2Active, not recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Sep 2018
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of atezolizumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Institut für Klinische Krebsforschung. Started Sep 2018; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03421288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03421288.